Sunday, March 1, 2015

Global and China Insulin Industry Report, 2013 - 2017

Researchmoz presents this most up-to-date research on"Global and China Insulin Industry Report, 2013 - 2017".The report focuses primarily on quantitative market metrics in order to characterize the growth and evolution of the Remote Patient Monitoring Market.

Click Here To Download Detail Report With TOC : http://www.researchmoz.us/global-and-china-insulin-industry-report-2013-2017-report.html

As the third largest human health disease following neoplastic disease, cardiovascular and cerebrovascular diseases, the number of diabetic patients has continued growing from 246 million in 2007 to 382 million in 2013 at a compound annual growth rate of 7.6%. And insulin as the important diabetes medication has also seen increasing market size. In 2012 the global insulin market size reached US$20.8 billion, a year-on-year rise of 12.9%, basically monopolized by Novo Nordisk, Sanofi and Eli Lilly, which altogether accounted for 88.7% of market share. 
Being the biggest diabetes power in the world, China currently has 98.4 million patients, accounting for about 25.8% of the world’s total. With the maturing of national health insurance system and improvement of economic level, the Chinese insulin drug market size has been on the rise, with the CAGR in 2007-2012 up to 25.4%, well above that of the global insulin market size, and it is expected to maintain a CAGR of at least 15% in the next few years.
Insulin has seen an increasing proportion of Chinese diabetes drug market, from 38.7% in 2007 to 55.6% in 2012. However, due to technical barriers, China’s insulin market is mainly occupied by Novo Nordisk, Sanofi and Eli Lilly, of which, Novo Nordisk accounted for 60.3% in 2012. While in recombinant human insulin market segments, the local Chinese enterprise –Tonghua Dongbao Pharmaceutical Co., Ltd. occupied part of the market with approximately 16% share.
Attracted by China’s tremendous diabetes drug market, multinational companies like Bayer, United Laboratories as well as the local Wanbang Biopharmaceuticals and Hisun Pharmaceutical are speeding up layout in China’s insulin market. Among them, Bayer Schering Pharma has obtained exclusive marketing and distribution rights of Poland’s Bioton insulin product “SciLin” in China as early as 2009; the recombinant Lispro Insulin of Wanbang Biopharmaceuticals has also received clinical approval issued by SFDA in September 2013.

Market Research Related Reports On Insulin Industry:Global and China Recombinant Human Insulin Industry 2013 Market Research Report http://www.researchmoz.us/global-and-china-recombinant-human-insulin-industry-2013-market-research-report-report.html

The report provides a basic overview of the industry including definitions, applications and industry chain structure. Global market analysis and Chinese domestic market analysis are provided with a focus on history, developments, trends and competitive landscape of the market. A comparison between the international and Chinese situation is also offered.Global and China Recombinant Human Insulin Industry Research Report 2013 also focuses on development policies and plans for the industry as well as a consideration of a cost structure analysis. Capacity production, market share analysis, import and export consumption and price cost production value gross margins are discussed.A key feature of this report is it focus on major industry players, providing an overview, product specification, product capacity, production price and contact information for Global Top15 companies. This enables end users to gain a comprehensive insight into the structure of the international and Chinese Recombinant Human Insulin industry. Development proposals and the feasibility of new investments are also analyzed.

China Insulin Industry Report, 2012-2015 http://www.researchmoz.us/china-insulin-industry-report-2012-2015-report.html

China is a country with the largest number of diabetics. In 2011, the market scale of diabetes medicine in China approximated RMB13.8 billion, of which, insulin medicines mainly comprising recombinant human insulin and insulin analog accounted for 52.8%.Due to high technological content and entry barriers, Chinese insulin market is monopolized by foreign corporations. In 2011, the combined market share of the three world-renowned pharmaceutical tycoons including Novo Nordisk, Eli Lilly and Company, and Sanofi Group hit 90% in the Chinese market. By contrast, the largest domestic counterpart- Tonghua Dongbao Pharmaceutical -occupied merely 3.4% or so.Denmark-based Novo Nordisk is not only the leader in global insulin industry, but also a major supplier in Chinas insulin market with the recombinant human insulin market share of 76% and the insulin analog market share of 53% in 2011.America-based Eli Lilly and Company is the second embarking on Chinese insulin market, with the recombinant human insulin market share of 17% and the insulin analog market share of 8% in 2011. Moreover, Eli Lilly and Company is making constant efforts to extend business in the Chinese market.

About Us:
ResearchMoz is the one stop online destination to find and buy market research reports. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets.
Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.


For More Information Kindly Contact:

Thursday, June 5, 2014

Rare Earth Markets in China

Jun 2nd 2014, 06:00, by admin : China's demand for Rare Earth has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2003, 2008 and 2013) and long-term forecasts through 2018 and 2023 are presented. Major producers in China are profiled.

Rare Earth Markets in China
Table Of ContentsI. Introduction
Report Scope and Methodology
Executive Summary


II. Business Environment
Economic Outlook
Key Economic Indicators
Industrial Sales Volume
Population and Labor
Foreign Investment
Foreign Trade
Financial and Tax Regulations
Banking System and Regulations
Foreign Exchange
Taxes, Tariff and Custom Duties


III. Rare Earth Industry Assessments
Rare Earth Industry Structure
Market Size
Major Producer Facility Location
Major Producer Capacity and Output
Market Share of Key Producers
Labor Cost
Potential Entrants
Foreign Investments
Technology Development


IV. Rare Earth Production and Demand
Overview
Rare Earth Production and Demand (metric tons)
Rare Earth Output
Rare Earth Exports and Imports
Rare Earth Demand
Pricing Trends


V. Rare Earth Consumption by Market
Rare Earth Markets Outlook
Electronics
Electronics Industry Trends
Rare Earth Consumption in Electronic Industry
Chemical Industry
Chemical Industry Trends
Rare Earth Consumption in Chemical Industry


VI. Marketing Strategies
China Market Entry Overview
China's Distribution System
Rare Earth Distribution Channels
Transportation and Freight Infrastructure
Communications
China's Market Entry
Export to China
Indirect Export
Direct Export
License and Contract Manufacture
Assembling in China
Contract Manufacturing
Trade Permit
Investment
Equity Joint Venture
Contractual Joint Venture
Wholly Foreign-Owned Enterprise


VII. Rare Earth Producer Directory
Rare Earth Producer Profiles
Distributors and Trading Companies


Original Post Rare Earth Markets in China

China Chemical Pharmaceutical Industry Report, 2013-2016

China Chemical Pharmaceutical Industry Report, 2013-2016

Jun 4th 2014, 06:00, by admin

Chemical pharmaceutical consists mainly of chemical drug preparation and active pharmaceutical ingredient (API), and the gross margin of chemical drug preparation industry is generally higher than that of the API over the same period. In 2013, China chemical drug preparation industry and and China API industry recorded revenue of RMB 573.1 billion and RMB 382 billion, with gross margin of 35%-40% and 20%, respectively. China is a big producer of chemical APIs, capable of producing about 1,600 varieties of APIs. China ranks first worldwide in output of several bulk APIs including penicillins, vitamins and antipyretic analgesics, and holds a significant share of the featured APIs like statins, prils, sartans in the world. China produced 2.709 million tons of chemical APIs in 2013. Although China is the world's leading chemical APIs supply region, the concentration of China chemical APIs industry is rather low due to numerous categories of APIs and limited overall strength of domest

Original Post China Chemical Pharmaceutical Industry Report, 2013-2016

High Voltage Cables Markets in China

High Voltage Cables Markets in China

Jun 3rd 2014, 06:00, by admin

China's demand for High Voltage Cables has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2003, 2008 and 2013) and long-term forecasts through 2018 and 2023 are presented. Major producers in China are profiled.

Original Post High Voltage Cables Markets in China

Machine Tools Markets in China

Machine Tools Markets in China

Jun 3rd 2014, 06:00, by admin

China's demand for Machine Tools has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2003, 2008 and 2013) and long-term forecasts through 2018 and 2023 are presented. Major producers in China are profiled.

Original Post Machine Tools Markets in China

Global and China Aluminum Electrolytic Capacitor Market Report, 2013-2016

Global and China Aluminum Electrolytic Capacitor Market Report, 2013-2016

Jun 4th 2014, 06:00, by admin

Currently, Japanese manufacturers dominate the supply of the global aluminum electrolytic capacitors, four of which rank among top five players worldwide, namely Chemi-con, Nichicon, Rubycon and Panasonic, totally enjoyed 64% of the global share in 2013, and followed by Taiwan-based companies with 14%. In 2013, Mainland China produced about 109.5 billion aluminum electrolytic capacitors, up 9.5% year on year; it gained the sales revenue of RMB10.4 billion, representing a year-on-year increase of 9.47%. As the global aluminum electrolytic capacitor manufacturing is shifting to Mainland China, Japan, South Korea, Taiwan and Hong Kong manufacturers have set up their plants in Mainland China in recent years. Under the context of energy saving and emission reduction era, aluminum electrolytic capacitors not only grow steadily in the field of traditional consumer electronics, but also witness extended application in many emerging fields (such as energy-saving lamps, inverters, new ener

Original Post Global and China Aluminum Electrolytic Capacitor Market Report, 2013-2016

China Vitamin Industry Report,2014-2017

China Vitamin Industry Report,2014-2017

Jun 4th 2014, 06:00, by admin

China is the world's largest production base of vitamins, with vitamin C and vitamin E as its most important products, wherein vitamin C and related products account for more than 60% of its total output and vitamin E takes up about 30%. Since 2009, influenced by the sluggish external demand and declining prices, China's output of vitamin products has been declining sharply. In 2013, the output of various types of vitamin products in China was about 201,000 tons, down 7.4% YoY. China is also the world's largest export base of vitamins, mainly vitamin C, vitamin E and pantothenic calcium. In 2013, China's export volume of vitamin C and vitamin E accounted for 55.0% and 23.7% of total export volume over the same period. In addition, the proportions of D or DL-pantothenic acid (i.e. vitamin B3 or B5) have increased to 5.7%. Chinese vitamin producers fall into two types: large integrated pharmaceutical enterprises and professional vitamin producers. In 2009-2013, large integrated pha

Original Post China Vitamin Industry Report,2014-2017